ImmuCell Corporation (ICCC)

Market Cap	28.20M
Revenue (ttm)	23.84M
Net Income (ttm)	-3.81M
Shares Out	7.83M
EPS (ttm)	-0.49
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,933
Open	3.400
Previous Close	3.600
Day's Range	3.400 - 3.690
52-Week Range	3.340 - 5.590
Beta	0.57
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2024

About ICCC

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides Califor...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 30, 1987
• Employees: 79
• Stock Exchange: NASDAQ
• Ticker Symbol: ICCC
• Website: https://immucell.com

Financial Performance

In 2023, ImmuCell's revenue was $17.47 million, a decrease of -5.90% compared to the previous year's $18.57 million. Losses were -$5.77 million, 131.6% more than in 2022.